Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice

Clinical and Experimental Immunology

Volumn 116, Issue 3, 1999, Pages 534-541

  Jonsson, Charlotte A ^a   Svensson, L ^a   Carlsten, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cyclophosphamide; Glomerulonephritis; MRLlpr mice; Mycophenolate mofetil; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; HEMATURIA; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ALKYLATING AGENTS; ANIMALS; ANTIBODIES, ANTINUCLEAR; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; IMMUNOGLOBULINS; IMP DEHYDROGENASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED MRL LPR; MYCOPHENOLIC ACID; SPLEEN;

EID: 0033034832     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00901.x     Document Type: Article

References (37)

1. Theofilopoulos AN, Dixon KJ. Murine models for systemic lupus erythematosus. Adv Immunol 1985; 37:269-393.
2. Altman A, Theofilopoulos A, Weiner R et al. Analysis of T cell function in autoimmune murine strains. J Exp Med 1981; 154:791-808.
3. Wofsy D, Murphy ED, Roths JB et al. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med 1981; 154:1671-80.
4. Dauphińe M, Kipper S, Wofsy D et al. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981; 127:2483-7.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
6. Wu J, Zhou T, He J et al. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993: 178:161-8.
7. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7:96-112.
8. Hao L, Chan S-M, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann N Y Acad Sci 1993; 696:328-32.
9. Chanaud NP. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 1995; 61:429-34.
10. Kitchin JE, Pomeranz MK, Pak G et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37:445-9.
11. Goldblum R. Therapy of rheumatoid arthritis with Mycophenolate Mofetil. Clin Exp Rheumatol 1993; 11:117-9.
12. Böhm M, Beissert S, Schwarz T et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349:541.
13. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350:494.
14. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
15. Dooley MA, Nachman PH, Satterly KK et al. Mycophenolate mofetil therapy in resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN) following cyclophosphamide (CyP) therapy [abstract]. Arthritis Rheum 1997; 40 (Suppl. 9):58.
16. Russell PJ, Hicks JD. Cyclophosphamide treatment of renal disease in (NZBxNZW) Fl hybrid mice. Lancet 1968; 1:440-6.
17. Boumpas DT, Austin HA III, Vaughn EM et al. Controlled trial of pulse inethylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741-5.
18. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34:945-50.
19. Tarkowski A, Gunnarsson K, Nilsson L-Ä et al. Successful treatment of autoimmunity in MRL/I mice with LS 2616, a new immunomodulator. Arthritis Rheum 1986; 29:1405-9.
20. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochem 1965; 2:235-54.
21. Carlsten H, Tarkowski A, Holmdahl R et al. Ocstradiol is a potent disease accelerator in SLE prone MRL lpr/lpr mice. Clin Exp Immunol 1990; 80:467-73.
22. Czerkinsky C, Nilsson L-Å, Nygren H et al. A solid phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. J Immunol Methods 1983; 65:109-21.
23. Smith HR, Chused TM, Steinberg AD. Cyclophosphamide-induced changes in the MRL-lpr/lpr mouse: effects upon cellular composition, immune function and disease. Clin Immunol Immunopathol 1984; 30:51-61.
24. Coma D, Morigi M, Facchinetti D et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51:1583-9.
25. McMurray RW, Elbourne KB, Lal S. Mycophenolale mofetil prevents lupus nephritis and mortality in the female B/W mouse model of SLE [abstract]. Arthritis Rheum 1997; 40 (Suppl. 9):324.
26. Van Bruggen MC, Walgreen B, Rijke TP et al. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9:1407-15.
27. Berden JH, Kaaber P, Assman KJ et al. Effects of cyclosporin A on autoimmune disease in MRL/I and BXSB mice. Scand J Immunol 1986; 24:405-12.
28. Mountz JD, Smith HR, Wilder RL et al. Cs-A therapy in MRLlpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol 1987; 138:157-63.
29. Entani C, Izumino K, Iida H et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 1993; 64:471-5.
30. Xu X, Blinder L, Shen J et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997; 159:167-74.
31. Austin HA III, Klippel JH, Balow JE et al. Therapy of lupus nephritis. N Engl J Med 1986; 314:614-9.
32. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1997; 39:1475-82.
33. Boumpas DT, Austin HA III, Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366-9.
34. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective anti-proliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33:175-83.
35. Kelley VE, Roths JB. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 1985; 37:220-9.
36. Allison AC, Kowalski WJ, Muller CJ et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25:67-70.
37. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62:1363-6.